Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.

Trial Profile

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2020.
    • 12 Jul 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
    • 12 Jul 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top